Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children
Efficacy and Safety Study of Eslicarbazepine Acetate (BIA 2 093) as Adjunctive Therapy for Refractory Partial Seizures in Children
The purpose of this study is to examine the efficacy and safety of Eslicarbazepine acetate (BIA 2-093) when given with other anti-epileptic drugs to treat children with partial seizures whose condition has not been controlled by other drug treatments.
Partial epilepsy, the commonest form of epilepsy, is a difficult condition to treat with many patients continuing to have symptoms despite trying several medications. Lack of efficacy and adverse effects are commonly associated with current anti-epileptic drugs.
This study will examine the efficacy in addition to safety and tolerability of a new anti-epileptic drug, Eslicarbazepine acetate (BIA 2-093), as an adjunctive therapy for refractory partial seizures in children.
The primary analysis variables are:
Inclusion Criteria:
Exclusion Criteria:
Vienna, 1090, Austria
Banja Luka, 78000, Bosnia and Herzegovina
Sarajevo, 71000, Bosnia and Herzegovina
Paris, 75015, France
Kehl-Kork, 77694, Germany
Miskolc, 3526, Hungary
Siena, 53100, Italy
Kelantan, Kelantan 15586, Malaysia
Kuala Selangor, Selangor 43400, Malaysia
Chishinau, 2004, Moldova
Cebu City, Cebu 6000, Philippines
Santa Cruz, Manila 1003, Philippines
Katowice, 40-752, Poland
Poznan, 60-355, Poland
Timișoara, 300011, Romania
Moscow, 127412, Russia
Nizhny Novgorod, 603081, Russia
Voronezh, 394024, Russia
Yekaterinburg, 620149, Russia
Belgrade, 11000, Serbia
Niš, 18000, Serbia
Novi Sad, 21000, Serbia
Kiev, 04209, Ukraine
Newcastle upon Tyne, NE1 4LP, United Kingdom